semaglutide news november 2025 PRESS Novo Nordisk to present new data in oral in obesity and pipeline at ObesityWeek® Minnesota doctor says FDA weight-loss

The most well-studied transporter of the endocellular membranes is the mitochondrial carnitine/acylcarnitine carrier (CAC

26, 2026: When Novo Nordisk filed suit against Hims & Hers in early February, the case immediately drew attention as a high-stakes patent fight over semaglutide and what it could mean for the broader multi-billion-dollar market for GLP-1 treatments

Additionally, avacopan demonstrated its superiority in terms of sustained remission at 52 weeks, further evidencing its advantages over prednisone-based treatment plans

In real-world practice, the oral GLP-1 vs injectable decision often comes down to balancing clinical outcomes with patient lifestyle